The FDA approvals of 2010

The FDA didn't break any new drug approval records in 2010. According to data provided by Bloomberg, only 21 new drugs got the green light last year--fewer than both 2009 and 2008, when 25 and 24 were approved, respectively. However, 2010 was better than 2007, when regulators set the all-time low mark of 18 approvals.

Six biologics and 15 small molecule drugs passed FDA inspection last year. And it doesn't seem as if there will be many banner years in the future, as the FDA gets tougher with safety data and places new warnings on existing drugs. Unlike 2009, when several companies brought multiple new drugs to the market, no drugmaker in 2010 had more than one new drug approved. A list of 2010 CBER approvals, such as Provenge and Prevnar-13, can be found here.

Click here to begin the slideshow.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.